MedTrace Logo

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

NCT05783596 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2026-03-16

No results posted yet for this study

Summary

The purpose of this study is to determine how effective and safe the combination of glofitamab and obinutuzumab is in treating patients with Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) who have not received other treatments for their lymphoma.

The names of the study drugs involved in this study are:

* Glofitamab (a type of immunotherapy)
* Obinutuzumab (a type of immunotherapy)

Conditions

Interventions

DRUG

Obinutuzumab

Humanized glycoengineered type II anti-CD20 monoclonal antibody, via IV infusion.

DRUG

Glofitamab

T-cell bispecific humanized monoclonal antibody, via IV infusion.

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Reid Merryman, MD

    lead OTHER

Principal Investigators

  • Reid Merryman, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-18
Primary Completion
2026-08-31
Completion
2029-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05783596 on ClinicalTrials.gov